SCHEMBL4861401

SCHEMBL4861401

O=C(O)c1ccc(F)cc1Nc1ccc(I)cc1Cl

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 7/20 0.64
CLCN2 P51788 1/20 0.54
MAP2K2 P36507 3/20 0.48
FABP3 P05413 1/20 0.47
FABP4 P15090 1/20 0.47
ALOX15 P16050 2/20 0.44
PYGL P06737 1/20 0.43
RAF1 P04049 1/20 0.43
PDGFRB P09619 1/20 0.43
CSNK2A2 P19784 1/20 0.43
CSNK2B P67870 1/20 0.43
CSNK2A1 P68400 1/20 0.43
CSNK2A3 Q8NEV1 1/20 0.43
AURKC Q9UQB9 1/20 0.43
CAMK2A Q9UQM7 1/20 0.43
IDO1 P14902 2/20 0.42
PTPRC P08575 1/20 0.42
PTPN2 P17706 1/20 0.42
PTPN1 P18031 1/20 0.42
PTPRA P18433 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5385826 0.86 MAP2K1 (0.52) MAP2K1CLCN2MAP2K2ALOX15PYGL
SCHEMBL1488709 0.86 MAP2K1 (0.70) MAP2K1CLCN2MAP2K2IDO1
SCHEMBL5680894 0.86 MAP2K1 (0.55) MAP2K1CLCN2MAP2K2FABP3FABP4
SCHEMBL29413438 0.86 MAP2K1 (0.70) MAP2K1CLCN2MAP2K2IDO1
SCHEMBL4855220 0.84 MAP2K1 (0.66) MAP2K1MAP2K2FABP3FABP4RAF1
SCHEMBL4855512 0.83 IDO1 (0.61) MAP2K1CLCN2MAP2K2IDO1PTPRC
SCHEMBL6035937 0.83 MAP2K1 (0.53) MAP2K1CLCN2MAP2K2FABP3FABP4
SCHEMBL27563916 0.80 MAP2K1 (0.50) MAP2K1CLCN2MAP2K2FABP3FABP4
SCHEMBL6951921 0.80 CLCN2 (0.51) MAP2K1CLCN2MAP2K2FABP3FABP4
SCHEMBL4851728 0.80 MAP2K1 (0.58) MAP2K1MAP2K2RAF1PDGFRBCSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0993437-B1 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS WARNER LAMBERT CO (US) 2006-11-08 EP claimed
US-20030149015-A1 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives BARRETT STEPHEN DOUGLAS (US) 2003-08-07 US claimed
JP-2003504400-A 2003-02-04 JP claimed
CN-1373660-A Method for treating chronic pain using MEK inhibitors WARNER LAMBERT CO (US) 2002-10-09 CN claimed
EP-1202726-A2 METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-05-08 EP claimed
US-20020022647-A1 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives BARRETT STEPHEN DOUGLAS (US) 2002-02-21 US claimed
US-6310060-B1 FOR USE AS ANTIPROLIFERATIVE AGENT FOR USE AGAINST CANCER, PSORIASIS, RESTENOSIS, AUTOIMMUNE DISEASE, OR ATHEROSCLEROSIS WARNER-LAMBERT COMPANY 2001-10-30 US claimed
WO-2001005392-A2 METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-01-25 WO claimed
EP-0993437-A1 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-04-19 EP claimed
WO-1999001421-A1 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 1999-01-14 WO claimed
EP-1301472-B1 OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS WARNER LAMBERT CO (US) 2014-03-26 EP disclosed
EP-1301472-B1 OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS WARNER LAMBERT CO (US) 2014-03-26 EP disclosed
US-7411001-B2 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids WARNER-LAMBERT COMPANY (US) 2008-08-12 US disclosed
US-7411001-B2 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids WARNER-LAMBERT COMPANY (US) 2008-08-12 US disclosed
US-7411001-B2 Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids WARNER-LAMBERT COMPANY (US) 2008-08-12 US disclosed
US-20040039208-A1 Process for making n-aryl-anthranilic acids and their derivatives CHEN MICHAEL HUAI GU (US) 2004-02-26 US disclosed
CN-1458921-A Process for making N-aryl-anthranilic acid and their derivatives WARNER LAMBERT CO (US) 2003-11-26 CN disclosed
EP-1313694-A1 PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES WARNER-LAMBERT COMPANY (US) 2003-05-28 EP disclosed
US-6492363-B2 FOR THERAPY OF CANCER AND OTHER PROLIFERATIVE DISEASES SUCH AS INFLAMMATION, PSORIASIS AND RESTENOSIS, AS WELL AS STROKE, HEART FAILURE, AND IMMUNODEFICIENCY DISORDERS WARNER-LAMBERT COMPANY 2002-12-10 US disclosed
WO-2002018319-A1 PROCESS FOR MAKING N-ARYL-ANTHRANILIC ACIDS AND THEIR DERIVATIVES WARNER-LAMBERT COMPANY LLC (US) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149015-A1 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives BCOR, BCL6, CBR1 MAP2K1 349/4885CLCN2 3718/4885MAP2K2 161/4885
US-20040039208-A1 Process for making n-aryl-anthranilic acids and their derivatives AADAC, AHR, AADAT MAP2K1 2455/4885CLCN2 4823/4885MAP2K2 1983/4885
US-20020022647-A1 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives BCOR, BCL6, CBR1 MAP2K1 349/4885CLCN2 3718/4885MAP2K2 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.